MedImmune, LLC - Product Pipeline Review - 2016 Summary Global Markets Direct's, ‘MedImmune, LLC - Product Pipeline Review - 2016', provides an overview of the MedImmune, LLC's pharmaceutical research and development focus. The report provides comprehensive information on the therapeutics under development by MedImmune, LLC, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and the dormant and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis. The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data. Scope - The report provides a snapshot of the pipeline therapeutic landscape of MedImmune, LLC - The report provides overview of MedImmune, LLC including its business description, key facts, and locations and subsidiaries - The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities - The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages - The report assesses MedImmune, LLC's pipeline therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type - The report features MedImmune, LLC's out-licensed and partnered product portfolio and summarizes its dormant and discontinued projects Reasons to Buy - Evaluate MedImmune, LLC's strategic position with total access to detailed information on its product pipeline - Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Identify and understand important and diverse types of therapeutics under development for MedImmune, LLC - Identify potential new clients or partners in the target demographic - Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics - Devise corrective measures for pipeline projects by understanding MedImmune, LLC's pipeline depth and focus of pipeline therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope
Table of Content
Table of Contents 2 List of Tables 5 List of Figures 5 MedImmune, LLC Snapshot 6 MedImmune, LLC Overview 6 Key Information 6 Key Facts 6 MedImmune, LLC - Research and Development Overview 7 Key Therapeutic Areas 7 MedImmune, LLC - Pipeline Review 14 Pipeline Products by Stage of Development 14 Pipeline Products - Monotherapy 15 Pipeline Products - Combination Treatment Modalities 16 Pipeline Products - Partnered Products 17 Pipeline Products - Out-Licensed Products 19 MedImmune, LLC - Pipeline Products Glance 21 MedImmune, LLC - Late Stage Pipeline Products 21 MedImmune, LLC - Clinical Stage Pipeline Products 23 MedImmune, LLC - Early Stage Pipeline Products 27 MedImmune, LLC - Drug Profiles 30 MEDI-550 30 anifrolumab 32 benralizumab 34 durvalumab 37 durvalumab + tremelimumab 41 influenza [strains A/H1N1 + A/H3N2 + B/Yamagata + B/Victoria] (quadrivalent) vaccine 43 moxetumomab pasudotox 44 tralokinumab 46 inebilizumab 48 dusigitumab 51 INO-3112 53 mavrilimumab 55 MEDI-2070 57 MEDI-3902 58 MEDI-4893 59 MEDI-6012 61 MEDI-7510 63 MEDI-8852 65 MEDI-8897 66 tremelimumab 67 inebilizumab + MEDI-0680 70 MEDI-0382 71 AMG-211 72 AMP-110 74 AMP-224 76 durvalumab + gefitinib 78 durvalumab + MEDI-0680 79 durvalumab + MEDI-6383 80 inebilizumab + rituximab 81 MEDI-0562 82 MEDI-0639 84 MEDI-0680 85 MEDI-1814 86 MEDI-1873 87 MEDI-3617 88 MEDI-3617 + tremelimumab 89 MEDI-4166 90 MEDI-4276 91 MEDI-4920 92 MEDI-6383 93 MEDI-7836 94 MEDI-8111 95 MEDI-9197 96 MEDI-9447 97 Oncolytic Virus to Activate IFN-b for Hepatocellular Carcinoma and Head And Neck Cancer Squamous Cell Carcinoma 98 respiratory syncytial virus vaccine 1 100 respiratory syncytial virus vaccine 2 101 MEDI-5117 102 264-RAD 103 Biologics for Acute Coronary Syndrome 104 EVT-770 105 MEDI-5304 106 MEDI-9314 107 Monoclonal Antibody Conjugates to Inhibit DNA Synthesis for Solid and Hematological Tumors 108 Monoclonal Antibody to Inhibit ILT7 for Systemic Lupus Erythematosus 109 PRO-391 110 V-2L2MD 111 ALM 112 Monoclonal Antibodies for Cancer 113 Monoclonal Antibody to Antagonize ECA for Enterobacteriaceae Infections 114 Recombinant Proteins for Cancer 115 MedImmune, LLC - Pipeline Analysis 116 MedImmune, LLC - Pipeline Products by Target 116 MedImmune, LLC - Pipeline Products by Route of Administration 119 MedImmune, LLC - Pipeline Products by Molecule Type 120 MedImmune, LLC - Pipeline Products by Mechanism of Action 121 MedImmune, LLC - Recent Pipeline Updates 124 MedImmune, LLC - Dormant Projects 145 MedImmune, LLC - Discontinued Pipeline Products 148 Discontinued Pipeline Product Profiles 149 MedImmune, LLC - Company Statement 153 MedImmune, LLC - Locations And Subsidiaries 155 Head Office 155 Other Locations & Subsidiaries 155 MedImmune, LLC - Key Manufacturing Facilities 157 Appendix 158 Methodology 158 Coverage 158 Secondary Research 158 Primary Research 158 Expert Panel Validation 158 Contact Us 158 Disclaimer 159
List of Tables
MedImmune, LLC, Key Information 11 MedImmune, LLC, Key Facts 11 MedImmune, LLC - Pipeline by Indication, 2016 14 MedImmune, LLC - Pipeline by Stage of Development, 2016 19 MedImmune, LLC - Monotherapy Products in Pipeline, 2016 20 MedImmune, LLC - Combination Treatment Modalities in Pipeline, 2016 21 MedImmune, LLC - Partnered Products in Pipeline, 2016 22 MedImmune, LLC - Partnered Products/ Combination Treatment Modalities, 2016 23 MedImmune, LLC - Out-Licensed Products in Pipeline, 2016 24 MedImmune, LLC - Out-Licensed Products/ Combination Treatment Modalities, 2016 25 MedImmune, LLC - Pre-Registration, 2016 26 MedImmune, LLC - Phase III, 2016 27 MedImmune, LLC - Phase II, 2016 28 MedImmune, LLC - Phase I, 2016 29 MedImmune, LLC - Phase 0, 2016 31 MedImmune, LLC - IND/CTA Filed, 2016 32 MedImmune, LLC - Preclinical, 2016 33 MedImmune, LLC - Discovery, 2016 34 MedImmune, LLC - Pipeline by Target, 2016 121 MedImmune, LLC - Pipeline by Route of Administration, 2016 124 MedImmune, LLC - Pipeline by Molecule Type, 2016 125 MedImmune, LLC - Pipeline Products by Mechanism of Action, 2016 126 MedImmune, LLC - Recent Pipeline Updates, 2016 129 MedImmune, LLC - Dormant Developmental Projects,2016 150 MedImmune, LLC - Discontinued Pipeline Products, 2016 153 MedImmune, LLC, Other Locations 160 MedImmune, LLC, Subsidiaries 161 MedImmune, LLC, Key Manufacturing Facilities 162
List of Figures
MedImmune, LLC - Pipeline by Top 10 Indication, 2016 13 MedImmune, LLC - Pipeline by Stage of Development, 2016 19 MedImmune, LLC - Monotherapy Products in Pipeline, 2016 20 MedImmune, LLC - Combination Treatment Modalities in Pipeline, 2016 21 MedImmune, LLC - Partnered Products in Pipeline, 2016 22 MedImmune, LLC - Out-Licensed Products in Pipeline, 2016 24 MedImmune, LLC - Pipeline by Target, 2016 121 MedImmune, LLC - Pipeline by Route of Administration, 2016 124 MedImmune, LLC - Pipeline by Top 10 Molecule Type, 2016 125 MedImmune, LLC - Pipeline Products by Top 10 Mechanism of Action, 2016 126
Global automotive coatings market size is likely to be valued at USD 27.7 billion by 2022; as per a new research report by Radiant Insights, Inc. Vehicle aesthetics, UV radiation and temperature variation protection and enhance durability are certainRead More...
Global contact lenses market size is estimated to reach USD 12.5 billion by 2020, according to a new industry report by Radiant Insights, Inc. Growing number of ophthalmic disorder observed in global population especially children is likely to driveRead More...
Global alpha olefins market size is likely to be valued at USD 10.7 billion by 2020; as per a new research report by Radiant Insights, Inc. Increasing polyethylene demand for use in plastic production is anticipated to drive market growth. Growing apRead More...
Global gold nanoparticles market size is expected to reach 4.99 billion by 2020, witnessing gains at a CAGR of 24.7%. Positive outlook towards the increasing applications of nanotechnology in medical and dentistry such as drug delivery systems, nanomRead More...
Global aquafeed market size is anticipated to be valued at USD 165.04 billion by 2022, as per a new research report by Radiant Insights, Inc. Increase in fish consumption for direct and indirect consumer applications is anticipated to drive the markeRead More...
Toll Free: 1-888-928-9744
Email: [email protected]
Speak to the report author to design an exclusive study to serve your research needs.
A testimonial for service excellence represented in the form of BBB "A" Accreditation.
Your personal and confidential information is safe and secure.